1- Abouzid, K; Frohberg, P; Lehmann, J; and Decker, M; 6-Aryl-4-oxohexanoic acids: Synthesis, effects on eicosanoid biosynthesis, and anti-inflammatory in vivo-activities.

Med.Chem; 3, 433-438, 2007.

2- Ulbrich, H; Fiebich, B; & Dannhardt, G., Cyclooxygenase-1/2 (COX-1/COX-2) and 5-Lipoxygenase (5-LOX) Inhibitors of the 6, 7-Diaryl-2,3-1H-dihydropyrrolizine Type.

ChemInform, 34 (20), 2003.

3- Dannhardt, G; & Laufer, S., Structural Approaches to Explain the Selectivity of COX-2 Inhibitors: Is There a Common Pharmacophore?

Current Medicinal Chemistry, 7(11), 1101-1112, 2000.

4- Kim, H.-J; Chae, C. H; Yi, K. Y; Park, K.-L; & Yoo, S., Computational studies of COX-2 inhibitors: 3D-QSAR and docking.

Bioorganic & Medicinal Chemistry, 12(7), 1629-1641, 2004.

5- Almansa, C; de Arriba, A. F; Cavalcanti, F. L; Gómez, L. A; Miralles, A; Merlos, M; Forn, J., Synthesis and SAR of a New Series of COX-2-Selective Inhibitors:  Pyrazolo(1,5-a) pyrimidines.

Journal of Medicinal Chemistry, 44(3), 350-361, 2001.

6- Tsujii, M; Kawano, S; Tsuji, S; Sawaoka, H; Hori, M; & DuBois, R. N.,

Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells.

Cell, 93(5), 705-716, 1998.

7- Tsujii, M; Kawano, S; & DuBois, R. N., Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proceedings of the National Academy of Sciences, 94(7), 3336-3340, 1997.

8- Asanuma M and Miyazaki I. Nonsteriodal anti-inflammatory drugs in experimental Parkinsonian models and Parkinson’s disease. Curr. Pharm. Des., 14:1428-1434, 2008.

9- Breitner, J. C. & Zandi, P. P. Do nonsteroidal anti-inflammatory drugs reduce the risk of Alzheimer’s disease?

2001. Engl. J. Med. 345, 1567-1568, 2001.

10- McGeer, P. L; Rogers, J. & McGeer, E. G. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years.

2006. Alzheimers Dis., 9, 271-276 , 2006.

11- Cao H, Yu R, Choi Y, Ma ZZ, Zhang H, Xiang W, Lee DYW, Berman BM, Moudgil KD, Fong HHS: Discovery of cyclooxygenase inhibitors from medicinal plants used to treat inflammation.

Pharmacol Res., 61: 519-524. 10.1016/j.phrs. 02.007, 2010.

12- Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data, 343: 1-19, 2004.

13- Lesley Braun, Marc Cohen. Herbs and Natural Supplements an evidence-based guide. 3ed ed. Churchill Livingstone, 2010.

14- Tringali, C., In: Bioactive Compounds from Natural Sources Taylor & Francis, London, p.98, 2001.

15- Newman, D. J. and G. M. Cragg., Natural products as sources of new drugs over the last 25 years.

2007. Nat. Prod., 70: 461-477, 2007.

16- Thiry, A; et al., Ligand-based and structure-based virtual screening toidentify carbonic anhydrase IX inhibitors.

Bioorg. Med. Chem., 17 (2), 553-557, 2009.

17- Kavitha, R; et al., Pharmacophore modeling, virtual screening, moleculardocking studies and density functional theory approaches to identify novelketohexokinase (KHK) inhibitors. Biosystems, 138, 39-52, 2015.

18- Vuorinen, A; et al., Ligand-based pharmacophore modeling and virtualscreening for the discovery of novel 17 -hydroxysteroid dehydrogenase 2inhibitors.

2014. Med. Chem., 57 (14), 5995-600, 2014.

19-  https://www.rcsb.org/

20- Khanna, I. K; Weier, R. M; Yu, Y; Xu, X. D; Koszyk, F. J; Collins, P. W;  Isakson, P. C., 1, 2-Diarylimidazoles as Potent, Cyclooxygenase-2 Selective, and Orally Active Anti- inflammatory Agents.

Journal of Medicinal Chemistry, 40(11), 1634-1647, 1997.

21- Gerhard Wolber, Thierry Langer, Ligand-Scout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters.

2005. J. Chem. Inf. Model, 45 (1), 160-169, 2005.

22- Elmira, N; Sajjad, Gh., Toward a hierarchical virtual screening and toxicity risk analysis for identifying novel CA XII inhibitors.

BioSystems, 162, 35-43, 2017.

23- Vuorinen, A; Schuster, D., Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling Methods 71, 113-134, 2015.

24- Ambure, P; Kar, S; Roy, K..

Pharmacophore mapping-based virtual screeningfollowed by molecular docking studies in search of potentialacetylcholinesterase inhibitors as anti-Alzheimer’s agents. Biosystems, 116, 10-20, 2014.

25- Mysinger, M.M; et al., Directory of useful decoys, enhanced (DUD-E): betterligands and decoys for better benchmarking.

2012. Med. Chem., 55 (14), 6582-6594, 2012.

26- Huang, N; Shoichet, B.K; Irwin, J.J., Benchmarking sets for molecular docking.

2006. Med. Chem., 49 (23), 6789-6801, 2006.

27- Karaboga, A. S; Planesas, J. M; Petronin, F; Teixidó, J; Souchet, M; & Pérez-Nueno, V. I., Highly SpecIfic and Sensitive Pharmacophore Model for Identifying CXCR4 Antagonists. Comparison with Docking and Shape-Matching Virtual Screening Performance.

Journal of Chemical Information and Modeling, 53(5), 1043-1056, 2013.

28- Seal, A; et al., Enhanced ranking of PknB Inhibitors using data fusion methods.

2013. Cheminf. 5 (1), 1, 2013.

29- Chitranshi, N; et al., New molecular scaffolds for the design of Alzheimer’s acetylcholinesterase inhibitors identified using ligand-and receptor-based virtual screening. Med. Chem. Res., 22 (5), 2328-2345, 2013.

30- 30Lu, S.-H; et al., The discovery of potential acetylcholinesterase inhibitors: acombination of pharmacophore modeling, virtual screening, and molecular docking studies.

2011. Biomed. Sci., 18 (1), 1, 2011.

31- Chen, Z; et al., Pharmacophore-based virtual screening versus docking-based virtual screening: a benchmark comparison against eight targets.

Acta Pharmacol. Sin., 30 (12), 1694-1708, 2009.

32- Irwin, Sterling, Mysinger, Bolstad, Coleman, ZINC: A Free Tool to Discover Chemistry for Biology.

2012. Chem. Inf. Model, 52 (7), 1757-1768, 2012.

33- Lipinski, C.A., Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods, 44 (1), 235-249, 2000.

34- Harder, E; Damm, W; Maple, J; Wu, C; Reboul, M; Xiang, J. Y; et al., OPLS3: A force field providing broad coverage of drug-like small molecules and proteins.

Journal of Chemical Theory and Computation, 12(1), 281-296, 2016.

35- Storer, J. W; Giesen, D. J; Cramer, C. J; & Truhlar, D. G., Class IV charge models: A new semi empirical approach in quantum chemistry. Journal of Computer-Aided Molecular Design, 9(1), 87-110, 1995.

36- Madhavi Sastry, G; Adzhigirey, M; Day, T; Annabhimoju, R; & Sherman, W., Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. Journal of Computer-Aided Molecular Design, 27(3), 221-234, 2013.

37- Du, J; Sun, H; Xi, L; Li, J; Yang, Y; Liu, H; et al., Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime/MMGBSA calculation. Journal of Computational Chemistry, 32(13), 2800-2809, 2011.

38- Friesner, R.A; Murphy, R.B; Repasky, M.P; Frye, L.L; Greenwood, J. R; (39) Halgren,T. A; et al., Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein−ligand complexes.

Journal of Medicinal Chemistry, 49(21), 6177-6196, 2006.

39- Friesner, R. A; Banks, J. L; Murphy, R. B; Halgren, T. A; Klicic, J. J; Mainz, D. T; … Shenkin, P. S., Glide:  A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. Journal of Medicinal Chemistry, 47(7), 1739-1749, 2004.

40- E. Nazarshodeh, S. Gharaghani, ‘Toward a hierarchical virtual screening and toxicity risk analysis for identifying novel CA XII inhibitors’.

Biosynthesis, 162, 35- 43, 2017.

41- Picot, D; Loll, P. J; & Garavito, R. M. , The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1.

Nature, 367(6460), 243-249, 1994.

42- Smith, W. L; Garavito, R. M; & DeWitt, D. L., Prostaglandin endo peroxide H synthases (cyclooxygenases)-1 and −2. Journal of Biological Chemistry, 271 (52), 33157-33160, 1996.

43- Orlando, B. J; & Malkowski, M. G., Crystal structure of rofecoxib bound to human cyclooxygenase-2. Acta Crystallographica Section F Structural Biology Communications, 72(10), 772-776, 2016.

44- http://zinc.docking.org/

45- Noreen, Y; Serrano, G; Perera, P; & Bohlin, L., Flavan-3-ols Isolated from Some Medicinal Plants Inhibiting COX-1 and COX-2 Catalysed Prostaglandin Biosynthesis.

Planta Medica, 64 (06), 520-524, 1998.

46- Gibbons, S.,

Bioactive compounds from natural sources isolation, characterization and biological properties.

Phytotherapy  Research, 16 (6), 600-600, 2002.